AUGMENT-102: A Phase 1, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability and Preliminary Anti-Leukemic Activity of SNDX-5613 in Combination with Chemotherapy in Patients with Relapsed/Refractory Leukemias Harboring a KMT2A/MLL Gene Rearrangement or Nucleophosmin 1 Mutation (mNPM1)

Is this Study for You?

Let's Get Started!


Child to Adult

Type of Study



Childrens Hospital Colorado

Principal Investigator
Photograph of Kelly Faulk,  MD

Kelly Faulk, MD

Study ID

Protocol Number: 21-4798

More information available at NCT05326516


Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers